title: Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats.
abstract: Severing the axons of retinal ganglion cells (RGC) by crushing the optic nerve (ONC) causes the majority of RGC to degenerate and die, primarily by apoptosis. We showed recently that after ONC in adult rats, caspase-2 activation occurred specifically in RGC while no localisation of caspase-3 was observed in ganglion cells but in cells of the inner nuclear layer. We further showed that inhibition of caspase-2 using a single injection of stably modified siRNA to caspase-2 protected almost all RGC from death at 7 days, offering significant protection for up to 1 month after ONC. In the present study, we confirmed that cleaved caspase-2 was localised and activated in RGC (and occasional neurons in the inner nuclear layer), while TUNEL⁺ RGC were also observed after ONC. We then investigated if suppression of caspase-2 using serial intravitreal injections of the pharmacological inhibitor z-VDVAD-fmk (z-VDVAD) protected RGC from death for 15 days after ONC. Treatment of eyes with z-VDVAD suppressed cleaved caspase-2 activation by >85% at 3-4 days after ONC. Increasing concentrations of z-VDVAD protected greater numbers of RGC from death at 15 days after ONC, up to a maximum of 60% using 4000 ng/ml of z-VDVAD, compared to PBS treated controls. The 15-day treatment with 4000 ng/ml of z-VDVAD after ONC suppressed levels of cleaved caspase-2 but no significant changes in levels of cleaved caspase-3, -6, -7 or -8 were detected. Although suppression of caspase-2 protected 60% of RGC from death, RGC axon regeneration was not promoted. These results suggest that caspase-2 specifically mediates death of RGC after ONC and that suppression of caspase-2 may be a useful therapeutic strategy to enhance RGC survival not only after axotomy but also in diseases where RGC death occurs such as glaucoma and optic neuritis.
authors.affiliation: Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
authors.forename: Vasanthy
authors.initials: V
authors.lastname: Vigneswara
authors.forename: Martin
authors.initials: M
authors.lastname: Berry
authors.forename: Ann
authors.initials: A
authors.lastname: Logan
authors.forename: Zubair
authors.initials: Z
authors.lastname: Ahmed
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D019771:Axotomy; D053143:Caspase 2 / Q000378:metabolism*; D061945:Caspase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D019610:Cytoprotection / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D005260:Female; D058449:Intravitreal Injections; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D009900:Optic Nerve / Q000166:cytology / Q000187:drug effects / Q000502:physiology / Q000601:surgery; D051381:Rats; D017207:Rats, Sprague-Dawley; D012165:Retinal Ganglion Cells / Q000187:drug effects* / Q000502:physiology
chemical_list: D061945:Caspase Inhibitors; D009842:Oligopeptides; C427308:benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone; D053143:Caspase 2